Next, we analysed CD3+CD4+ and CD3+CD4− cells using SAM, a statistical method used to identify features from input data described by a response variable, to determine previously described T cell activation markers that substantially differed between MS patients and controls. The gene discussed is CD4; the disease is myeloid sarcoma.